Ecker G, Helml T, Fleischhacker W, Noe C R, Studenik C, Schade B, Heistracher P
Institut für Pharmazeutische Chemie, Universität Wien, Osterreich.
Arch Pharm (Weinheim). 1995 Apr;328(4):343-8. doi: 10.1002/ardp.19953280410.
The benzofuranethanamines 3a and 3b were synthesized and pharmacologically tested to investigate structure-activity relationships with antiarrhythmic compounds. The key-step in the synthesis was the chemoselective reduction of the chloroacetyl-dihydrobenzofurane 5 to chloroethylbenzofurane 9 using triethylsilane/BF3.Et2O. Results of a series of further attempts to reduce 5 are also described. Pharmacological investigations on isolated guinea pig heart muscle preparations showed that 3a exhibits similar negative inotropic and negative chronotropic action in comparison to propafenone and the conformationally restricted benzofurane 1a. In contrast to these substances, however, 3a shows no beta 1-adrenoreceptor blocking activity.
合成了苯并呋喃乙胺3a和3b,并进行了药理测试,以研究其与抗心律失常化合物的构效关系。合成的关键步骤是使用三乙基硅烷/三氟化硼乙醚将氯乙酰基二氢苯并呋喃5化学选择性还原为氯乙基苯并呋喃9。还描述了一系列进一步还原5的尝试结果。对离体豚鼠心肌制剂的药理研究表明,与普罗帕酮和构象受限的苯并呋喃1a相比,3a表现出相似的负性肌力和负性变时作用。然而,与这些物质不同的是,3a没有β1肾上腺素能受体阻断活性。